




































































































































































































































































































































































































0.043 0.617 0.386 0.986
FIGO
I/II	versus	III/IV
0.000 0.360 0.207 0.626
Grading
G1	versus	G2/3
0.001 0.365 0.202 0.660
Age
<	60	versus	≥	60	years








0.002 2.783 1.463 5.294
FIGO
I/II	versus	III/IV
0.000 0.347 0.200 0.601
Grading
G1	versus	G2/3
0.000 0.343 0.191 0.618
Age
<	60	versus	≥	60	years
0.210 0.769 0.509 1.160
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Figures
Figure	1
Positive	and	negative	control	staining	for	THRα	antibodies	used:	(a)	THRα	staining	in	Struma
tissue	(10x	lens).	(b)	THRα1	staining	in	colon	tissue	(10x	lens).	(c)	THRα2	staining	in
placental	tissue	(10x	lens).	(d)	THRα1	negative	control	in	colon	tissue	(10x	lens).	(e)	THRα2
negative	control	in	placental	tissue	(10x	lens).	(f)	THRα	staining	in	Struma	tissue	(25x	lens).
(g)	THRα1	staining	in	colon	tissue	(25x	lens).	(h)	THRα2	staining	in	placental	tissue	(25x
lens).	(i)	THRα1	negative	control	in	colon	tissue	(25x	lens).	(j)	THRα2	negative	control	in
placental	tissue	(25x	lens).
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Figure	2
(a)	THRα	expression	in	serous	carcinoma	(10x	lens).	(b)	THRα	expression	in	clear	cell
carcinoma	(10x	lens).	(c)	THRα	expression	in	endometrioid	carcinoma	(10x	lens).	(d)	THRα
expression	in	mucinous	carcinoma	(10x	lens).	(e)	summary	of	THRα	expression	in	different
carcinoma	subtypes	(nuclear	expression).	(f)	THRα	expression	in	serous	carcinoma	(25x
lens).	(g)	THRα	expression	in	clear	cell	carcinoma	(25x	lens).	(h)	THRα	expression	in
endometrioid	carcinoma	(25x	lens).	(i)	THRα	expression	in	mucinous	carcinoma	(25x	lens).
(j)	summary	of	THRα	expression	in	different	carcinoma	subtypes	(cytoplasmic	expression).
24
Figure	3
Kaplan–Meier	estimates	of	THRα	expression,	THRα1	expression	and	THRα2	expression	were
analyzed.	In	the	clear	cell	subtype,	patients	with	a	high	nuclear	expression	of	THRα	showed
a	significantly	reduced	overall	survival	compared	with	patients	with	a	low	nuclear
expression	(a).	In	addition,	high	nuclear	THRα1	expression	was	associated	with	significantly
better	overall	survival	in	all	ovarian	cancer	subtypes	compared	to	patients	with	a	low
nuclear	THRα1	expression	(b).	Patients	with	high	THRα1	expression	in	the	cytoplasm	and
mucinous	subtype	had	a	significantly	decreased	overall	survival	compared	with	those
mucinous	carcinoma	patients	with	low	cytoplasmic	expression	(c).	High	cytoplasmic	THRα2
expression	was	associated	with	a	significantly	reduced	overall	survival	in	all	ovarian	cancer
subtypes	compared	to	patients	with	a	low	cytoplasmic	THRα2	expression	(d).	In	the	serous
subtype,	patients	with	a	high	nuclear	expression	of	THRα2	showed	a	significantly	better
overall	survival	compared	with	patients	with	a	low	nuclear	expression	(e).	Finally,	in	the
clear	cell	subtype,	patients	with	a	high	nuclear	expression	of	THRa2	showed	a	significantly
reduced	very	low	overall	survival	(all	patients	deceased	within	two	years)	compared	to
patients	with	a	low	nuclear	expression	(f).
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Figure	4
Comparison	of	Immunohistochemical	staining	results	of	the	different	THR	(median	values)	in
the	nucleus	of	the	high-	and	low-grade	serous	ovarian	cancer	subtypes.	(IRS:
Immunoreactive	Score,	THR:	Thyroid	Receptor).	The	expression	of	THRα2	in	the	nucleus	is
significantly	different	in	low-grade	compared	to	high-grade	serous	carcinomas	(marked	by
an	asterisk).
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